Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting-Reference-Cited by-同舟云学术

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting

Published:2024-04-25 Issue:5 Volume:316 Page:
ISSN:1432-069X
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Rompoti Natalia,Stefanaki Irene,Panagakis Pantelis,Vavouli Charitomeni,Politou Maria,Papoutsaki Marina,Befon Aggeliki,Koutsa Fiori,Lazou Eleni,Koumprentziotis Ioannis-Alexios,Chasapi Vasiliki,Stratigos Alexander,Nicolaidou Electra

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00403-024-02868-7.pdf

Reference5 articles.

1. Reich K, Papp KA, Blauvelt A et al (2021) Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [published correction appears in Lancet. ;397(10275):670]. Lancet. 2021;397(10273):487–498. https://doi.org/10.1016/S0140-6736(21)00125-2

2. Gordon KB, Foley P, Krueger JG et al (2021) Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. ;397(10280):1182]. Lancet. 2021;397(10273):475–486. https://doi.org/10.1016/S0140-6736(21)00126-4

3. Warren RB, Blauvelt A, Bagel J et al (2021) Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med 385(2):130–141. https://doi.org/10.1056/NEJMoa2102388

4. Gordon KB, Langley RG, Warren RB et al (2023) Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled data from up to three years of treatment in randomized phase 3 trials. Br J Dermatol Published Online November 10. https://doi.org/10.1093/bjd/ljad429

5. Gargiulo L, Narcisi A, Ibba L et al (2023) Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne) 10:1243843 Published 2023 Aug 8. https://doi.org/10.3389/fmed.2023.1243843